Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Ospemifene has been evaluated primarily in postmenopausal women with moderate to severe vulvovaginal atrophy (VVA) and genitourinary syndrome of menopause (GSM), showing improvements in subjective and objective signs of atrophy and sexual function. In breast cancer survivors, ospemifene demonstrated effectiveness in treating GSM and vulvovaginal atrophy, potentially enhancing quality of life.
• The studies included women undergoing treatments for GSM, with findings indicating that ospemifene is a viable treatment option among nonestrogen therapies, providing benefits similar to other treatments while maintaining a favorable safety profile, notably with no significant endometrial concerns after up to 52 weeks of use.
• Ospemifene demonstrated a favorable safety profile in the treatment of genitourinary syndrome of menopause (GSM) and vulvovaginal atrophy (VVA), with post-treatment endometrial thickness remaining within the recognized safe range (under 4 mm) and no cases of endometrial carcinoma or hyperplasia observed after up to 52 weeks of treatment.
• The drug was associated with a minimal increase in adverse events compared to other nonestrogen therapies, and specific safety concerns for breast cancer survivors regarding ospemifene were not detailed.
• Ospemifene was assessed primarily in postmenopausal women with moderate to severe vulvovaginal atrophy (VVA) and breast cancer survivors (BCS), showing effectiveness in improving symptoms of genitourinary syndrome of menopause (GSM) and vulvovaginal atrophy; however, specific subgroup differences in effectiveness were not detailed.